Lantheus Holdings, Inc. $LNTH Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 75,347 shares of the medical equipment provider’s stock after selling 8,265 shares during the quarter. New York State Teachers Retirement System’s holdings in Lantheus were worth $3,865,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Assenagon Asset Management S.A. bought a new position in shares of Lantheus during the third quarter worth about $65,654,000. Norges Bank acquired a new stake in Lantheus during the second quarter valued at approximately $32,631,000. Galvin Gaustad & Stein LLC bought a new position in Lantheus during the 2nd quarter worth approximately $11,899,000. Boston Partners grew its position in shares of Lantheus by 30.5% in the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after acquiring an additional 134,781 shares in the last quarter. Finally, Frontier Capital Management Co. LLC grew its position in shares of Lantheus by 52.1% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 315,513 shares of the medical equipment provider’s stock worth $25,828,000 after acquiring an additional 108,060 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 1.8%

Shares of NASDAQ:LNTH opened at $64.25 on Friday. The company has a market cap of $4.26 billion, a PE ratio of 27.00 and a beta of -0.11. The company’s 50-day moving average price is $62.19 and its 200 day moving average price is $60.90. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, hitting the consensus estimate of $1.27. The firm had revenue of $384.01 million during the quarter, compared to analysts’ expectations of $363.42 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. Lantheus’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on LNTH shares. Mizuho upped their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial boosted their target price on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.